keyword
MENU ▼
Read by QxMD icon Read
search

Flozins AND diabetes

keyword
https://www.readbyqxmd.com/read/26911584/sglt-2-receptor-inhibitors-for-treating-patients-with-type-2-diabetes-mellitus-a-systematic-review-and-network-meta-analysis
#1
Deepson S Shyangdan, Olalekan A Uthman, Norman Waugh
OBJECTIVE: Because of the lack of head-to-head trials, the aim was to indirectly compare sodium glucose transporter-2 (SGLT-2) inhibitors in the treatment of type 2 diabetes. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: MEDLINE and EMBASE were searched from January 2005 to January 2015. ELIGIBILITY CRITERIA: Randomised controlled trials assessing the efficacy of SGLT-2 inhibitors in patients with type 2 diabetes inadequately controlled with diet and exercise alone or metformin monotherapy...
2016: BMJ Open
https://www.readbyqxmd.com/read/26679969/demographic-and-clinical-profiles-of-type-2-diabetes-mellitus-patients-initiating-canagliflozin-versus-dpp-4-inhibitors-in-a-large-u-s-managed-care-population
#2
COMPARATIVE STUDY
Michael Grabner, Xiaomei Peng, Caroline Geremakis, Jay Bae
BACKGROUND: Canagliflozin is the first sodium-glucose co-transporter-2 (SGLT-2) inhibitor-a new class of oral antidiabetic (OAD) medication-approved for type 2 diabetes mellitus (T2DM) treatment in the United States. Approved less than 2 years ago, use of canagliflozin is largely uncharacterized. OBJECTIVE: To investigate and compare baseline demographic, clinical, and economic characteristics of patients initiating canagliflozin and dipeptidyl peptidase-4 (DPP-4) inhibitors in the real-world setting...
December 2015: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/24130972/sglt2-inhibition-with-dapagliflozin-a-novel-approach-for-the-management-of-type-2-diabetes
#3
REVIEW
Gary Kilov, Stephen Leow, Merlin Thomas
BACKGROUND: Because of the progressive nature of the disease, most patients with type 2 diabetes mellitus eventually require multiple treatments to achieve glycaemic targets. The majority of available therapies are insulin dependent, aiming to decrease insulin resistance and increase insulin secretion. Sodium glucose co-transporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents, limit renal glucose reabsorption promoting urinary excretion of glucose, thereby reducing plasma glucose...
October 2013: Australian Family Physician
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"